Immunoliposomes: a promising approach to targeting cancer therapy.
Immunoliposomes (antibody-coupled liposomes) have been regarded as very attractive drug-targeting systems for chemotherapeutic cancer treatment. Fundamental problems regarding immunoliposome preparation and application such as antibody coupling and immunoliposome stability and pharmacokinetics have been overcome during the last decade. Therefore, several promising studies on tumour targeting have been described in recent years. Adding to existing reviews on liposomal drug delivery, this article focuses on immunoliposome tumour targeting and summarises various experiments of immunoliposome application in vitro and in vivo with respect to structural liposomal parameters, therapeutic potential and the requirements of the target sites. New therapeutic trends related to immunoliposomes are also considered. Remaining problems in immunoliposome application, especially immunological aspects, are discussed, as are strategies that might help to overcome these obstacles.
Bendas
G
G
Department of Pharmacy, Martin Luther University Halle, Wolfgang Langenbeck Strasse 4, 06120 Halle, Germany. bendas@pharmazie.uni-halle.de
D000818:Animals; D000906:Antibodies / Q000008:administration & dosage*; D002462:Cell Membrane / Q000378:metabolism; D016503:Drug Delivery Systems / Q000379:methods*; D004358:Drug Therapy / Q000379:methods; D006801:Humans; D008081:Liposomes; D010743:Phospholipids / Q000378:metabolism; D011092:Polyethylene Glycols / Q000008:administration & dosage* / Q000493:pharmacokinetics; D012997:Solvents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D014407:Tumor Cells, Cultured / Q000378:metabolism
D000906:Antibodies; D008081:Liposomes; D010743:Phospholipids; D012997:Solvents; D011092:Polyethylene Glycols